PFIZER PILL | BCRX Message Board Posts


BioCryst Pharmaceuticals Inc.

  BCRX website

BCRX   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  12772 of 12785  at  9/8/2021 7:53:32 AM  by

moegrabbedmythumb

The following message was updated on 9/8/2021 7:56:04 AM.

 In response to msg 12771 by  frnktofini
view thread

Re: PFIZER PILL

  
It might be time to look at the stock AIM Immunotech (current market cap $97 million):  
 

OCALA, Fla., Aug. 25, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today provided an update on the company’s efforts to develop its drug Ampligen as a potential intranasal therapeutic for COVID-19, including the announcement of a new provisional patent application for Ampligen as both an intranasal and an intravenous therapy for what AIM describes as Post-COVID-19 Cognitive Dysfunction (PCCD). 

Patients with symptoms of PCCD being treated with Ampligen in the ongoing AMP-511 Early Access Program have reported consistent improvements in cognitive function. Early data has demonstrated that patients with symptoms of PCCD being treated with Ampligen in the ongoing AMP-511 Early Access Program (EAP) have reported improvements in cognitive function, according to Charles Lapp, MD, at Hunter-Hopkins Center in Charlotte, N.C.

“The results of some individual symptoms are very dramatic,” said Lapp, the EAP’s lead investigator. “The results clearly show a significant reduction of one or more symptoms of PCCD in patients after the administration of Ampligen.”

 
 


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 0  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
12773 Re: PFIZER PILL Motohead125 0 9/10/2021 1:09:37 PM


Financial Market Data provided by
.
Loading...